GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medy-Tox Inc (XKRX:086900) » Definitions » Cash Flow for Lease Financing

Medy-Tox (XKRX:086900) Cash Flow for Lease Financing : ₩-649 Mil (TTM As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Medy-Tox Cash Flow for Lease Financing?

Medy-Tox's Cash Flow for Lease Financing for the three months ended in Mar. 2024 was ₩-172 Mil. Medy-Tox's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-649 Mil.

Compared with last quarter (₩-163 Mil in Dec. 2023 ), Medy-Tox's Cash Flow for Lease Financing remained the same in Mar. 2024 (₩-172 Mil).

Medy-Tox Cash Flow for Lease Financing Historical Data

The historical data trend for Medy-Tox's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medy-Tox Cash Flow for Lease Financing Chart

Medy-Tox Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow for Lease Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -421.94 -628.01 -845.82 -584.29 -611.59

Medy-Tox Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow for Lease Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -134.24 -167.85 -146.60 -162.90 -171.75

Medy-Tox Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.


Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-649 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medy-Tox Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of Medy-Tox's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Medy-Tox (XKRX:086900) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medy-Tox Inc (XKRX:086900) » Definitions » Cash Flow for Lease Financing
Comparable Companies
XKRX:048410 XKRX:145020 XKRX:214450 XKRX:141080 XKRX:096530 XKRX:085660 XKRX:016790 XKRX:064550 XKRX:298380 XKRX:005250 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
641-4, Gak-Ri, Ochang-Eup, Cheongwon, KOR, 363885
Website
http://www.medytox.com
Medy-Tox Inc. is a Korea-based company engaged in the development, manufacture, and marketing of biopharmaceuticals. The company's main product is type-A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. The group provides its products under the brand names of Neuronox, Siax and others. It distributes its products within Korean and to overseas markets, such as Japan, China, Russia and Europe, among others.

Medy-Tox (XKRX:086900) Headlines

No Headlines